Hepatitis Forums
Advanced Liver Disease Main Forums => Advanced Liver Disease => Topic started by: Hep Editors on December 02, 2020, 11:39:07 am
-
The Food and Drug Administration has approved a regimen combining the immune checkpoint inhibitor Tecentriq (atezolizumab) and the targeted therapy Avastin (bevacizumab) for the treatment of people with inoperable or metastatic hepatocellular carcinoma, the most common type of liver cancer.
In the Phase III IMbrave150 study, Tecentriq plus Avastin reduced the risk of disease progression or death by 41%, prolonged overall survival and improved quality of life compared with standard-of-care treatment.
Read more...
https://www.hepmag.com/article/fda-approves-tecentriq-plus-avastin-liver-cancer